{"id":"bmdex","safety":{"commonSideEffects":[{"rate":null,"effect":"Immunosuppression"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Bone loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BMDex combines dexamethasone with other anti-myeloma agents to improve treatment outcomes in multiple myeloma patients. The drug is being evaluated in phase 3 trials as part of combination therapy regimens for myeloma, leveraging dexamethasone's immunosuppressive and anti-inflammatory properties alongside other established myeloma therapeutics.","oneSentence":"BMDex is a dexamethasone-based treatment designed to enhance the efficacy of proteasome inhibitors and immunomodulatory drugs in multiple myeloma.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:04:39.412Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (in combination therapy)"}]},"trialDetails":[{"nctId":"NCT01078454","phase":"PHASE3","title":"Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11","conditions":"Light Chain Deposition Disease, Primary Systemic Amyloidosis","enrollment":11},{"nctId":"NCT01277016","phase":"PHASE3","title":"A Trial for Systemic Light-chain (AL) Amyloidosis","status":"COMPLETED","sponsor":"European Myeloma Network B.V.","startDate":"2011-01","conditions":"AL Amyloidosis","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bortezomid","Melphalan","Dexametasone"],"phase":"phase_3","status":"active","brandName":"BMDex","genericName":"BMDex","companyName":"European Myeloma Network B.V.","companyId":"european-myeloma-network-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMDex is a dexamethasone-based treatment designed to enhance the efficacy of proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Used for Multiple myeloma (in combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}